A 2025 Cleveland Clinic study found that individuals with certain genetic profiles were up to 50% more likely not to lose weight on GLP-1 medications, while those with responsive profiles were up to 82% more likely to achieve significant weight loss
Beginning July 1, 2026, the Medicare GLP-1 Bridge Program may allow eligible Medicare Part D patients to access certain obesity-indicated GLP-1 medications, including Foundayo, Wegovy, and certain Zepbound formulations, for no more than $50 per month through December 31, 2027
and then spend real time on what the evidence does not show
If morning injection causes you so much nausea that you skip meals, miss workouts, or dread injection day, the metabolic costs of that stress and disruption far outweigh any circadian benefit
Oral naevus (mole) , a small, stable pigmented bump that has been present for years